 AbCellera Biologics Inc NASDAQ: ABCL has announced that a second antibody from its collaboration with Eli Lilly and Co NYSE: LLY, LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies. 